KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Acadia Pharmaceuticals (ACAD) over the last 13 years, with Q3 2025 value amounting to $21.6 million.

  • Acadia Pharmaceuticals' Other Operating Expenses rose 1479.56% to $21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.9 million, marking a year-over-year decrease of 17948.13%. This contributed to the annual value of $146.5 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Acadia Pharmaceuticals' Other Operating Expenses is $21.6 million, which was up 1479.56% from $20.7 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' Other Operating Expenses' 5-year high stood at $23.0 million during Q1 2024, with a 5-year trough of -$124.7 million in Q4 2024.
  • In the last 5 years, Acadia Pharmaceuticals' Other Operating Expenses had a median value of $6.7 million in 2021 and averaged $3.6 million.
  • Over the last 5 years, Acadia Pharmaceuticals' Other Operating Expenses had its largest YoY gain of 127678.46% in 2024, and its largest YoY loss of 79706.56% in 2024.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Other Operating Expenses stood at $2.6 million in 2021, then decreased by 5.78% to $2.4 million in 2022, then soared by 641.44% to $17.9 million in 2023, then plummeted by 797.07% to -$124.7 million in 2024, then skyrocketed by 117.36% to $21.6 million in 2025.
  • Its Other Operating Expenses was $21.6 million in Q3 2025, compared to $20.7 million in Q2 2025 and $20.4 million in Q1 2025.